Abstract:The microenvironment within solid tumors often becomes acidic due to various factors associated with abnormal metabolism and cellular activities, including increased lactate production as a result of dysregulated tumor glycolysis. Recently, we have identified multiple tumor microenvironment (TME) factors that potentiate regulatory T (Treg) cell function in evading anti-tumor immunosurveillance. Despite the strong correlation between lactate and acidity, the potential roles of acidity in intratumoral Treg cell adaptation and underlying molecular mechanisms have gone largely unstudied. In this study, we demonstrate that acidity significantly enhances immunosuppressive functions of nTreg cells, but not iTreg cells, without altering the expression of either FoxP3 or the cell surface receptors CD25, CTLA4, or GITR in these cells. Surprisingly, the addition of lactate, often considered a major contributor to increased acidity of the TME, completely abolished the acidity-induced enhancement of nTreg suppressive functions. Consistently, metabolic flux analyses showed elevated basal mitochondrial respiratory capacity and ATP-coupled respiration in acidity-treated nTreg cells without altering glycolytic capacity. Genome-wide transcriptome and metabolomics analyses revealed alterations in multiple metabolic pathways, particularly the one-carbon folate metabolism pathway, with reduced SAM, folate, and glutathione, in nTreg cells exposed to low pH conditions. Addition of a one-carbon metabolic contributor, formate, diminished the acidity-induced enhancement in nTreg cell suppressive functions, but neither SAM nor glutathione could reverse the phenotype. Remarkably, in vitro transient treatment of nTreg cells resulted in sustained enhancement of their functions, as evidenced by more vigorous tumor growth observed in mice adoptively receiving acidity-treated nTreg cells. Further analysis of intratumoral infiltrated T cells confirmed a significant reduction in CD8+ T cell frequency and their granzyme B production. In summary, our study elucidates how acidity-mediated metabolic reprogramming leads to sustained Treg-mediated tumor immune evasion.

Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Regulation of T cell antitumor immune response by tumor induced metabolic stress

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling

Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

T cell metabolic fitness in antitumor immunity

A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment

Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies

Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis

Acidity induces durable enhancement of Treg cell suppressive functions for tumor immune evasion

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance

Fatty acid metabolism of immune cells: a new target of tumour immunotherapy